Utilization of next generation sequencing in NET/NEC management and practice patterns: A prospective survey of global NET specialists
#3287
Introduction: Next generation sequencing based somatic tumor mutation as well as germline mutation data is being increasingly used in cancer management. Pan tumor type FDA approval for NTRK fusion, intermediated-high tumor mutation burden and MSI high status has paved way for tissue agnostic molecularly targeted therapies. Utilization of NGS in neuroendocrine tumor (NET) and neuroendocrine carcinoma (NEC) is currently unknown.
Aim(s): To understand current practice patterns of NET/NEC specialist with regards to utilization of molecular testing for somatic and germline mutations.
Materials and methods: This is a 49 question, prospective, online, survey-based study wherein 23 members of NET-CONNECT (https://net-connect.info/meet-the-experts/) from across European Union, UK, USA and Asia are collaborating. Study is IRB approved and de-identified data is stored at University of Kentucky servers.
Conference: 18th Annual ENETS Concerence (2021)
Presenting Author:
Authors: Chauhan A, Munir A, Hernando J, Leeuwaarde R, Zhang P,
To read the full abstract, please log into your ENETS Member account.